Daily Clinical Briefing · Educational reading for healthcare professionals
Adjunctive intravenous paracetamol may help acute pain, but the trial leaves clinically important uncertainty.
Failure to establish non-inferiority does not prove that adding intravenous paracetamol provides a clinically important benefit.
A patient with severe pain receives titrated intravenous morphine. Should 1 g of intravenous paracetamol routinely be added?
The trial considered here makes that question harder rather than giving a clean yes or no. It compares morphine plus placebo with the same morphine regimen plus intravenous paracetamol in adults with acute traumatic or non-traumatic pain. The important detail is that this is a non-inferiority trial.
The prespecified margin is one pain-score point. In the traumatic-pain group, the modified intention-to-treat analysis produces a confidence interval whose upper limit reaches 1.01 points, just beyond that margin. Recruitment also falls short of the planned target. Morphine alone therefore does not meet the stated non-inferiority criterion in that analysis.
That does not mean paracetamol has been proved superior.
Failure to demonstrate non-inferiority leaves a difference unresolved. It does not establish that morphine alone is inferior, nor that adding paracetamol produces a clinically important benefit. That distinction is particularly important when a confidence interval sits almost exactly on the chosen margin.
There are signals worth noticing. In non-traumatic pain, the 30-minute per-protocol difference is 0.8 points in favour of paracetamol, with a 95% confidence interval of 0.19–1.41. Rescue analgesia is needed by 2% of the paracetamol group compared with 13% receiving placebo. But that rescue-analgesia result is secondary and remains hypothesis-generating. Morphine use is similar between groups, so an opioid-sparing effect is not demonstrated.
Applicability also matters. The study includes selected stable adults with pain lasting less than 24 hours and excludes patients who have taken analgesia during the preceding eight hours. The primary outcome concerns early pain relief, with mainly short follow-up. Later pain, function and subsequent analgesic needs remain uncertain.
There is also no oral paracetamol group. The study can inform the decision to add intravenous paracetamol, but it cannot show that intravenous treatment is better than oral paracetamol when a patient can take medication by mouth.
The practical position is therefore measured. Titrate morphine to response, reassess comfort and adverse effects, and consider paracetamol as part of an individualised strategy. The aim is useful pain relief that reduces suffering and allows examination and investigation, rather than assuming that every patient needs intravenous paracetamol or a pain score of zero.
Autonomic dysreflexia after spinal cord injury can cause severe hypertension with reflex bradycardia, headache, flushing and sweating; recognising injuries at T6 or above and rapidly identifying bladder, catheter, bowel or heat triggers allows cause-directed treatment.
Adding intravenous paracetamol to titrated morphine for severe acute pain may provide additional analgesia, but non-inferiority results, secondary outcomes, selected participants and the absence of an oral comparator leave the size and clinical importance of any benefit uncertain.
Reassess the response to titrated morphine rather than treating a pain score in isolation. Consider paracetamol as part of an individualised analgesic strategy, but do not interpret this trial as a mandate for intravenous paracetamol. Separate the decision to add paracetamol from the choice of intravenous or oral administration.
A non-inferiority trial compares titrated intravenous morphine alone with morphine plus intravenous paracetamol. The upper limit of the 95% confidence interval is 1.01 points against a prespecified one-point non-inferiority margin. What conclusion is justified?
Non-inferiority is not established because the confidence interval extends beyond the prespecified margin. This does not prove that morphine alone is inferior or that adjunctive paracetamol is superior.
A stable adult receiving titrated intravenous morphine can take medication by mouth. The relevant trial compares intravenous paracetamol with placebo but includes no oral paracetamol group. What can be concluded about intravenous versus oral paracetamol?
A benefit of intravenous over oral paracetamol remains unproven. The trial tests whether intravenous paracetamol adds analgesia to morphine, not whether the intravenous route is superior to oral treatment.
A person with a T6 spinal cord injury develops severe headache, marked hypertension and a slow pulse. Bladder distension is identified. What action addresses the likely trigger?
Empty the distended bladder and address any causative catheter problem. Severe hypertension with reflex bradycardia is compatible with autonomic dysreflexia and should prompt an active search for the precipitating stimulus.
Daily Clinical Briefings are prepared using ChatGPT Pro from the show notes and educational output for that day’s episodes. Iain Beardsell then checks the briefing for accuracy.
This describes the current briefing process. Item-specific review dates are shown only where documented. The original podcasts remain the sources; MedPod’s briefing is additional educational material.
Read about MedPod’s editorial approach
Report an error or source concern — please include the article title and link, without patient-identifying information.
.svg)